Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy

Journal of Autoimmunity

Volumn 34, Issue 4, 2010, Pages 408-415

  Orban, Tihamer ^a   Farkas, Klara ^a   Jalahej, Heyam ^a   Kis, Janos ^a,b   Treszl, Andras ^a,c   Falk, Ben ^d   Reijonen, Helena ^d   Wolfsdorf, Joseph ^e   Ricker, Alyne ^a   Matthews, Jeffrey B ^f   Tchao, Nadio ^f   Sayre, Peter ^f   Bianchine, Pete ^g  

^a JOSLIN DIABETES CENTER   (United States)

^b Department of Internal Medicine   (Hungary)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Autoantigen specific regulatory T cells; Clinical trial; Insulin B chain immunotherapy; Type 1 diabetes mellitus

Indexed keywords

C PEPTIDE; CD4 ANTIGEN; INSULIN B CHAIN; INSULIN DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOTHERAPY; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 77952243765     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.10.005     Document Type: Article

References (50)

1. Baecher-Allan C., Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006, 212:203-216.
2. Lampeter E.F., Homberg M., Quabeck K., Schaefer U.W., Wernet P., Bertrams J., et al. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993, 341:1243-1244.
3. Orban T., Kis J., Szereday L., Engelmann P., Farkas K., Jalahej H., et al. Reduced CD4+ T-cell-specific gene expression in human type 1 diabetes mellitus. J Autoimmun 2007.
4. Spatz M., Eibl N., Hink S., Wolf H.M., Fischer G.F., Mayr W.R., et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003, 221:15-26.
5. Eibl N., Spatz M., Fischer G.F., Mayr W.R., Samstag A., Wolf H.M., et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin.Immunol. 2002, 103:249-259.
6. Filippi C., Bresson D., von Herrath M. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int Rev Immunol 2005, 24:341-360.
7. Yamazaki S., Bonito A.J., Spisek R., Dhodapkar M., Inaba K., Steinman R.M. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 2007, 110:4293-4302.
8. Monti P., Scirpoli M., Rigamonti A., Mayr A., Jaeger A., Bonfanti R., et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007, 179:5785-5792.
9. Goudy K.S., Tisch R. Immunotherapy for the prevention and treatment of type 1 diabetes. Int Rev Immunol 2005, 24:307-326.
10. Avni O., Lee D., Macian F., Szabo S.J., Glimcher L.H., Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002, 3:643-651.
11. Ramiya V.K., Shang X.Z., Pharis P.G., Wasserfall C.H., Stabler T.V., Muir A.B., et al. Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun. 1996, 9:349-356.
12. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis [see comments]. Science 1993, 261:1727-1730.
13. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993, 259:1321-1324. [see comments].
14. Allen H.F., Klingensmith G.J., Jensen P., Simoes E., Hayward A., Chase H.P. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care 1999, 22:1703-1707.
15. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
16. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005, 19:238-246.
17. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008.
18. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002, 346:1685-1691.
19. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-1076.
20. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
21. Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005, 435:224-228.
22. Kupila A., Sipila J., Keskinen P., Simell T., Knip M., Pulkki K., et al. Intranasally administered insulin intended for prevention of type 1 diabetes-a safety study in healthy adults. Diabetes Metab Res Rev 2003, 19:415-420.
23. Alleva D.G., Gaur A., Jin L., Wegmann D., Gottlieb P.A., Pahuja A., et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002, 51:2126-2134.
24. Tiittanen M., Huupponen J.T., Knip M., Vaarala O. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes 2006, 55:3446-3454.
25. Schatz D., Cuthbertson D., Atkinson M., Salzler M.C., Winter W., Muir A., et al. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus-a new surrogate measure of non-progression?. Pediatr Diabetes 2004, 5:72-79.
26. Vardi P., Dib S.A., Tuttleman M., Connelly J.E., Grinbergs M., Rabizadeh A., et al. Competitive insulin autoantibody RIA: prospective evaluation of subjects at high risk for development of Type I diabetes mellitus. Diabetes 1987, 36:1286-1291.
27. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
28. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994, 37:344-350.
29. Payton M.A., Hawkes C.J., Christie M.R. Relationship of 37,000 and 40,000-M triptic fragment of islet antigens in insulin dependent diabetes to the protein tyrosine phosphatase-like molekule IA-2(ICA 512). JCI 1995, 96:1506-1511.
30. Durinovic-Bello I., Boehm B.O., Ziegler A.G. Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity. J Autoimmun 2002, 18:55-66.
31. Kis J., Engelmann P., Farkas K., Richman G., Eck S., Lolley J., et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007, 81:654-662.
32. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 1999, 104:R63-R67.
33. Mannering S.I., Dromey J.A., Morris J.S., Thearle D.J., Jensen K.P., Harrison L.C. An efficient method for cloning human autoantigen-specific T cells. J Immunol Methods 2005, 298:83-92.
34. Oberg H.H., Wesch D., Lenke J., Kabelitz D. An optimized method for the functional analysis of human regulatory T cells. Scand J Immunol 2006, 64:353-360.
35. Akatsuka Y., Martin E.G., Madonik A., Barsoukov A.A., Hansen J.A. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens. 1999, 53:122-134.
36. Seitz S., Schneider C.K., Malotka J., Nong X., Engel A.G., Wekerle H., et al. Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc Natl Acad Sci U S.A. 2006, 103:12057-12062.
37. Giudicelli V., Chaume D., Lefranc M.P. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004, 32:W435-W440.
38. Fineberg S.E., Kawabata T.T., Finco-Kent D., Fountaine R.J., Finch G.L., Krasner A.S. Immunological responses to exogenous insulin. Endocr Rev 2007, 28:625-652.
39. Salk J., Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195:834-847.
40. Beebe G.W., Simon A.H., Vivona S. Long-term mortality follow-up of army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 1972, 95:337-346.
41. Moreland L.W., Morgan E.E., Adamson T.C., Fronek Z., Calabrese L.H., Cash J.M., et al. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum 1998, 41:1919-1929. [see comments].
42. Gold D.P., Smith R.A., Golding A.B., Morgan E.E., Dafashy T., Nelson J., et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. J Neuroimmunol 1997, 76:29-38.
43. Trauger R.J., Ferre F., Daigle A.E., Jensen F.C., Moss R.B., Mueller S.H., et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256-1264.
44. Roep B.O. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 1996, 45:1147-1156.
45. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
46. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204:1757-1764.
47. Bradshaw E.M., Kent S.C., Tripuraneni V., Orban T., Ploegh H.L., Hafler D.A., et al. Concurrent detection of secreted products from human lymphocytes by microengraving: cytokines and antigen-reactive antibodies. Clin Immunol 2008.
48. You S., Thieblemont N., Alyanakian M.A., Bach J.F., Chatenoud L. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 2006, 212:185-202.
49. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
50. Jonuleit H., Schmitt E., Kakirman H., Stassen M., Knop J., Enk A.H. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2002, 196:255-260.